{"id":"CU26167","slug":"therapeutic-strategy-for--CU26167","source":{"id":"CU26167","dataset":"techtransfer","title":"Therapeutic strategy for treating glioblastoma by targeting the LINC complex","description_":"<p>This technology identifies the LINC complex as a therapeutic target for glioblastoma to suppress tumor progression and prevent the emergence of a therapy-resistant mesenchymal state. </p>\r\r<h2>Unmet Need: Novel therapies strategy for glioblastoma</h2>\r\r<p>Glioblastoma is the most common and aggressive brain tumor, with a poor prognosis and inevitable recurrence. Although surgery, radiation, and chemotherapy remain the standard of care, diffuse tumor infiltration limits complete surgical removal, and a subset of glioblastoma cells can enter a treatment-resistant, stem-cell-like state that acts as a reserve pool for cancer proliferation following treatment. As a result, there is a critical need for novel therapeutic strategies that specifically target the mechanisms underlying glioblastoma progression and therapy resistance.</p>\r\r<h2>The Technology: Specific gene therapy to eliminate glioblastoma cells</h2>\r\r<p>This technology identifies the LINC complex as a novel therapeutic target for glioblastoma. Nesprin-2, a component of the LINC complex that connects the nucleus to the cytoskeleton, is critical for glioblastoma cell migration and proliferation. Unlike most normal brain cells, which predominantly express nesprin-1, glioblastoma cells rely on nesprin-2, creating a tumor-specific therapeutic vulnerability. RNA interference targeting nesprin-2 reduces tumor growth size and proliferation while suppressing the therapy-resistant, stem-cell-like state that drives disease recurrence.</p>\r\r<p>This technology has been validated with human glioblastoma patient samples in vitro and with mouse models in vivo.</p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Antisense oligonucleotide therapies for glioblastoma</li>\r<li>AAV-mediated miRNA gene therapies</li>\r<li>Targeted CRISPR-based therapeutic strategies</li>\r<li>Research tool for studying glioblastoma cell proliferation, migration and therapy resistance</li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Prevents the emergence of therapy-resistant mesenchymal-like cell state</li>\r<li>Targets a novel therapeutic pathway for glioblastoma treatment</li>\r<li>High tumor specificity through selective targeting of nesprin-2</li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://www.pathology.columbia.edu/profile/gregg-g-gundersen-phd\">Gregg G. Gundersen, Ph.D.</a></p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending</p>\r\r<h2>Related Publications:</h2>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li><p>IR CU26167</p></li>\r<li><p>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Jerry Kokoshka</a></p></li>\r</ul>\r","tags":["Cell migration","Cell nucleus","Cell proliferation","Chemotherapy","Cytoskeleton","Gene therapy","Glioblastoma","MicroRNA","Neoplasm","Oligonucleotide","Prognosis","RNA interference","Radiation therapy"],"file_number":"CU26167","collections":[],"meta_description":"Targeting the LINC complex, specifically nesprin-2, with RNAi/gene therapies to curb glioblastoma growth and therapy resistance.","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":3.0,\"timeliness\":4.0},\"weighted_score\":3.8,\"risks\":[\"Biological safety and off-target effects of nesprin-2 targeting\",\"Delivery challenges for CNS (blood-brain barrier)\",\"Potential resistance mechanisms\",\"Manufacturing/regulatory hurdles for gene therapy modalities\"],\"one_sentence_take\":\"High novelty and potential impact with early readiness, but translational hurdles and delivery/regulatory risks temper the overall prospect.\"}","inventors":["Gregg G. Gundersen","Osama Al Dalahmah","Susumu Antoku"],"manager":"Jerry Kokoshka","depts":["Pathology","Pathology & Cell Biology"],"divs":["Columbia University Medical Center (CUMC)"],"date_released":"2026-08-11"},"highlight":{},"matched_queries":null,"score":0.0}